u/tobias_vukovic

the label on a compounded vial is a legal document, read it

Paid noticeably more at one clinic than another for what turned out to be the same facility behind both.

the EMA authorises, member states decide who pays

DEXA has a meaningful coefficient of variation, and it differs between machines and protocols. Comparing scans from different clinics adds a systematic offset that is invisible on the report.

A beyond-use date derived from published stability data means something different from one assigned by default rule. Asking which is a fair question and the answer is usually available.

Correction: those scans are from different machines, and the difference you are describing is within the measurement error.

What does the local patient information leaflet say?

a shortage in one member state is not a shortage in all of them

Is the prescription from the same country as the pharmacy?

salt forms are the recurring argument and the answer is boring

Resistance training, and at what frequency?

Supply notices are issued nationally. A notice in one member state does not imply availability problems in another, even for the same product.

What is protein intake actually looking like, measured rather than estimated?

a 503B has to register and report, so there is a paper trail to ask for

Same view. If the intake asked you nothing, the intake was a formality and you should factor that in.

Concentration on the compounded vial was different from what I had been using and I nearly did the arithmetic on autopilot.

Push back: strength dropping in a deficit is not the same as lean mass loss. Related, not identical.

do not compare your composition to a trial average

Paid noticeably more at one clinic than another for what turned out to be the same facility behind both.

Agreed on potency testing of the finished preparation. That is a different question from the purity of the starting material.

a shortage in one member state is not a shortage in all of them

if a clinic will not name the facility, that is your answer

a 503B has to register and report, so there is a paper trail to ask for

Same view. If the intake asked you nothing, the intake was a formality and you should factor that in.

Not convinced by that DEXA comparison. Different machine, different protocol, and the difference is inside the error.

Push back: comparing headline prices across countries without normalising pack size is comparing two different quantities.

Reimbursed or private?

Salt form matters for mass: a preparation specified as one salt and dosed as the free base gives you a different amount of peptide for the same number on the label.

What was the rate of weight change over that window?

That figure is the starting material purity, not the finished preparation potency. Two different tests.

a 503B has to register and report, so there is a paper trail to ask for

Nothing here is medical or legal advice, and eligibility questions have national answers that a pharmacist where you live can give you in minutes.

Reminder that nothing here is medical advice and this board cannot tell you which arrangement to choose.

This is the distinction the whole board runs on. Everything else follows from it.

ask what the beyond-use date is based on

ask which facility, then ask for their testing

Criteria changed at plan renewal and the denial that had been immovable simply did not apply any more.

Concentration on the compounded vial was different from what I had been using and I nearly did the arithmetic on autopilot.

Reimbursed or private?

Right, and a shortage notice in one country tells you very little about the next one along.

strength retention is a decent proxy and it is free